Collaboration and License Agreements - Visirna Therapeutics Inc. (“Visirna”) and Genzyme Corporation (“Sanofi”) (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 01, 2025	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		$ 829,448	$ 3,551	$ 240,735
Sanofi | Sanofi License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price	$ 130,000
Future potential milestone payments	265,000
Revenue		$ 130,000
Fixed consideration	$ 130,000